Project Details
Description
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) with Pembrolizumab (KEYTRUDA) for Recurrent Glioblastoma or Gliosarcoma
| Status | Finished |
|---|---|
| Effective start/end date | 5/31/18 → 5/31/23 |
Funding
- DNATRIX, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.